Boston

Pharmalittle: Biogen defends its controversial Alzheimer’s drug – Boston, Massachusetts

Boston, Massachusetts 2021-07-22 09:24:02 –

HHello everyone. Today How are you? The shining sun and the soothing breeze surround the Pharmalot campus this morning. There, a short man departs for a summer job, and the official mascot is happily dozing in his corner. As for us, we are staring at a horrifying to-do list and a cup of inspiration. Maybe you can get involved? In any case, we have collected some items that you are interested in again to get started on your day. So go here. Keep us in mind when you conquer the world and come across something intriguing. …

Biogen (BIIB) The head of research and development issued an open letter to the Alzheimer’s disease community, which aimed directly at approved critics, and began aggressive defense of the controversial Alzheimer’s disease drug aducanumab., STAT Write. Alsandrock, director and architect of many of Biogen’s successes, writes that the purpose of this letter is to correct “misinformation and misunderstandings” about the drug and approval process.

Sign up for STAT + to unlock this article and enjoy the first 30 days for free!

let’s start



Pharmalittle: Biogen defends its controversial Alzheimer’s drug Source link Pharmalittle: Biogen defends its controversial Alzheimer’s drug

Back to top button